Dbrowska G, Kata A, Goc A, Szechyska-Hebda M, Skrzypek E
Take 5 to 10 seconds to deliver your full dose
W.ChungW
3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib (62)
Interestingly, researchers noticed that Fragment 176-191 only appeared to lead to weight loss in obese mice and did not appear to affect lean mice
An X, Shi X: Effects of electroconvulsive shock on neuro-immune responses: Does neuro-damage occur